Citizens downgrades Terns Pharmaceuticals stock on Merck deal

Citizens Financial Group investment arm has downgraded the stock of Terns Pharmaceuticals, a clinical-stage biopharmaceutical company. This move reflects a re-evaluation of Terns' competitive standing, largely influenced by recent strategic advancements and expanded presence of pharmaceutical giant Merck & Co. in therapeutic areas critical to Terns' pipeline. The downgrade signals a perceived increase in market risk or a diminished growth outlook for Terns. Such adjustments often occur when a major industry player like Merck intensifies its focus or acquires assets in a specific disease domain, thereby increasing competitive pressure on smaller, developing firms. For the broader biotechnology and pharmaceuticals sector, this event underscores the pervasive impact of big pharma's strategic maneuvers on the valuation and future trajectory of emerging companies, particularly those with novel drugs still undergoing clinical trials.